COVID-19: Oxford’s vaccine trials to continue after a subject’s death
Category: #health  | By Nikita Chaurasia  | Date: 2020-10-23 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

COVID-19: Oxford’s vaccine trials to continue after a subject’s death
  • The deceased volunteer was reportedly subjected to a placebo and not the actual COVID-19 vaccine.
  • The Brazilian government plans on purchasing the patent COVID-19 vaccine if approved.

According to reliable sources, the demise of a volunteer occurred during AstraZeneca’s and Oxford’s COVID-19 trials, currently being conducted in Brazil. Following the review of the of the unfortunate event, health surveillance authority Anvisa (Agência Nacional de Vigilância Sanitária) has reportedly authorized the study to proceed without any disruptions.

The deceased volunteer was subjected to a placebo and not the actual COVID-19 vaccine, sources confirmed. In fact, the effectuality of the potential vaccine was evaluated on only half of the volunteers participating in the trial.

In this context, AstraZeneca issued a statement claiming that all the medical events are carefully monitored by trial investigators along with an independent safety monitoring committee. Providing assurance regarding the authenticity of the trials, the company further stated that it had followed all the prerequisite review processes.

According to the University of Oxford, all significant medical incidents, including those concerning the participants in the control group or the COVID-19 vaccine group, are reviewed independently.

It is to be noted that AstraZeneca conducted its phase 1 and 2 trials for the potential vaccine candidate, while the phase 3 trial is currently being carried out in India, Brazil, and in the United Kingdom.

Reportedly, the Brazilian regulator has suggested that the companies to continue their trial round. Moreover, the Brazilian government plans on purchasing the patent COVID-19 vaccine if it is approved by the regulatory bodies.

Meanwhile, Brazil’s President Jair Bolsonaro has reportedly declared that the federal government will not buy a COVID-19 vaccine from China-based biopharmaceutical company Sinovac Biotech Ltd.

 

Source credits: https://www.bbc.com/news/world-latin-america-54634518

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

PM Liz Truss to launch comprehensive review of UK’s visa policy

PM Liz Truss to launch comprehensive review of UK’s visa policy

By Nikita Chaurasia

Newly appointed Prime Minister Liz Truss is considering doing a complete review of Britain's visa system, as the nation struggles with severe labor shortages in vital industries. Business leaders across the UK have reportedly praised the decision...

UAE: Entrepreneurs and investors can benefit from visa reforms

UAE: Entrepreneurs and investors can benefit from visa reforms

By Nikita Chaurasia

The visa and business reforms by the UAE will open new prospects for investors, entrepreneurs, IT specialists, job seekers, and tourists, according to credible sources. This will reportedly benefit the region’s economic growth. Business Link...

Flipkart introduces new tech and design upgrades ahead of holiday season

Flipkart introduces new tech and design upgrades ahead of holiday season

By Nikita Chaurasia

Flipkart, India's indigenous online marketplace, is reportedly offering customers an improved shopping experience on its widely popular app. To better serve various client groups that are exploring e-commerce during the holiday season, Flipkar...